This simulator demonstrates the incretin effect by letting you deliver a matched glucose dose either orally or intravenously and comparing the resulting insulin secretion curves side by side. It visualizes GLP-1 and GIP release from gut L-cells and K-cells following oral intake, shows how these hormones amplify beta cell insulin output only while blood glucose is elevated, and lets you toggle a type 2 diabetes mode to see how GIP potency loss and overall blunting shrink the gap between the oral and intravenous responses.
Choose a glucose delivery route, oral or intravenous, and set the glucose dose using the slider. Run the simulation to watch blood glucose, incretin hormone levels, and insulin secretion evolve over time on synchronized graphs. Switch between healthy and type 2 diabetes physiology to compare how the incretin amplification differs, and try administering a GLP-1 receptor agonist in diabetes mode to see how it restores much of the missing insulin boost without triggering release at normal glucose levels.
Glucose delivery route toggle (oral versus intravenous), glucose dose slider, physiology mode toggle (healthy versus type 2 diabetes), optional GLP-1 receptor agonist administration switch, and a run or reset control with synchronized time-course graphs for blood glucose, GLP-1, GIP, and insulin secretion.
Did you know the incretin effect was discovered simply by comparing oral and intravenous glucose tolerance tests, and that this single observation eventually led to an entire class of blockbuster medications used for both diabetes and weight loss? GLP-1 also has a half-life of only a few minutes in the body because it is rapidly broken down by an enzyme called DPP-4, which is why some diabetes drugs work by blocking that enzyme instead of directly supplying GLP-1 itself.
This simulator demonstrates the incretin effect by letting you deliver a matched glucose dose either orally or intravenously and comparing the resulting insulin secretion curves side by side. It visualizes GLP-1 and GIP release from gut L-cells and K-cells following oral intake, shows how these hormones amplify beta cell insulin output only while blood glucose is elevated, and lets you toggle a type 2 diabetes mode to see how GIP potency loss and overall blunting shrink the gap between the oral and intravenous responses.
This simulator demonstrates the incretin effect by letting you deliver a matched glucose dose either orally or intravenously and comparing the resulting insulin secretion curves side by side. It visualizes GLP-1 and GIP release from gut L-cells and K-cells following oral intake, shows how these hormones amplify beta cell insulin output only while blood glucose is elevated, and lets you toggle a type 2 diabetes mode to see how GIP potency loss and overall blunting shrink the gap between the oral and intravenous responses.
Choose a glucose delivery route, oral or intravenous, and set the glucose dose using the slider. Run the simulation to watch blood glucose, incretin hormone levels, and insulin secretion evolve over time on synchronized graphs. Switch between healthy and type 2 diabetes physiology to compare how the incretin amplification differs, and try administering a GLP-1 receptor agonist in diabetes mode to see how it restores much of the missing insulin boost without triggering release at normal glucose levels.
Did you know the incretin effect was discovered simply by comparing oral and intravenous glucose tolerance tests, and that this single observation eventually led to an entire class of blockbuster medications used for both diabetes and weight loss? GLP-1 also has a half-life of only a few minutes in the body because it is rapidly broken down by an enzyme called DPP-4, which is why some diabetes drugs work by blocking that enzyme instead of directly supplying GLP-1 itself.